The advanced electrocardiogram developer has set the range for an initial public offering sized at up to $91m, with Novo, Kaiser Permanente and St. Jude set to exit.
US-based cardiac diagnostics technology developer iRhythm Technologies set the terms yesterday for an initial public offering that will give an exit to pharmaceutical firm Novo.
The company will issue 5.35 million shares priced between $13.00 and $15.00, which would place the size of the IPO at $80.3m to $91m. Should the underwriters take up the option to acquire another 800,000 shares the size of the offering could reach almost $105m.
Founded in 2006 and spun out of Stanford University,…
